<div id="readability-page-1">Earnings Call Insights: Kestra Medical Technologies (KMTS) Q2 2026 Management View Brian Webster, President and CEO, highlighted strong financial performance in Q2, noting &#34;revenue was $22.6 million with growth of 53% over the prior year period.&#34; He emphasized the milestone of surpassing a 50% gross margin for the first time, stating &#34;actual gross ...</div>

IONM

<p>Kestra Medical Technologies 将其 FY26 收入指引上调至 9100 万美元，目标是实现超过 70% 的毛利率，得益于 ASSURE 系统的扩展。2026 年第二季度收入为 2260 万美元，同比增长 53%，毛利率为 50.6%。公司计划扩大销售区域并增加处方量，支持这一计划的是 ACE-PAS 研究的临床证据。运营费用为 4320 万美元，GAAP 净亏损为 (3280) 万美元。Kestra 旨在未来几年实现持续增长和改善毛利率</p>

Kestra 将 2026 财年的收入预期上调至 9100 万美元，并计划通过扩展 ASSURE 系统实现超过 70% 的毛利率